NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00093-7599-57 | 00093-7599 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | Oct. 31, 2018 | In Use |
00093-7600-41 | 00093-7600 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | Jan. 31, 2019 | In Use |
00093-7600-57 | 00093-7600 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | Jan. 31, 2019 | In Use |
00093-7601-41 | 00093-7601 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | July 31, 2019 | In Use |
00093-7601-57 | 00093-7601 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | July 31, 2019 | In Use |
00093-7602-57 | 00093-7602 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | Oct. 31, 2018 | In Use |
00093-7638-41 | 00093-7638 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | May 31, 2019 | In Use |
00093-7638-57 | 00093-7638 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | May 31, 2019 | In Use |
00093-7639-41 | 00093-7639 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | July 31, 2019 | In Use |
00093-7639-57 | 00093-7639 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug. 12, 2013 | July 31, 2019 | In Use |
00115-1675-72 | 00115-1675 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 21, 2016 | April 3, 2019 | In Use |
00115-1675-73 | 00115-1675 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 21, 2016 | Oct. 31, 2018 | In Use |
00173-0846-08 | 00173-0846 | Dabrafenib | Tafinlar | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | June 10, 2013 | Aug. 31, 2018 | No Longer Used |
00173-0847-08 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | June 10, 2013 | May 31, 2018 | No Longer Used |
00173-0847-61 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | June 10, 2013 | Dec. 11, 2014 | No Longer Used |
00173-0847-65 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Oct. 8, 2014 | May 31, 2018 | No Longer Used |
00179-0149-70 | 00179-0149 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | May 14, 2014 | March 31, 2016 | In Use |
00179-0165-70 | 00179-0165 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Oct. 10, 2014 | June 30, 2017 | In Use |
00179-0195-70 | 00179-0195 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 2, 2015 | Nov. 30, 2017 | In Use |
00179-0225-70 | 00179-0225 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Feb. 14, 2017 | Jan. 31, 2018 | In Use |
00310-0657-58 | 00310-0657 | Olaparib | Lynparza | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec. 24, 2014 | March 31, 2020 | No Longer Used |
00310-7820-30 | 00310-7820 | Vandetanib | Caprelsa | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | July 25, 2011 | May 31, 2020 | No Longer Used |
00310-7840-30 | 00310-7840 | Vandetanib | Caprelsa | 300.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | July 25, 2011 | May 31, 2020 | No Longer Used |
00338-3991-01 | 00338-3991 | ifosfamide | Ifex | 1.0 g/20mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 30, 1988 | In Use | |
00338-3993-01 | 00338-3993 | ifosfamide | Ifex | 3.0 g/60mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 30, 1988 | In Use |
Found 10,000 results in 4 milliseconds — Export these results